@phdthesis{10902/36426,
year = {2025},
month = {4},
url = {https://hdl.handle.net/10902/36426},
abstract = {La prevalencia de las enfermedades inflamatorias inmunomediadas (IMID) está incrementada en pacientes con enfermedad hepática grasa metabólica (MASLD). Para analizar esta relación, se realizó un estudio transversal casos-controles. Los resultados mostraron una mayor prevalencia de formas avanzadas de enfermedad hepática grasa (SLD) y MASLD en pacientes con IMID, independientemente de los factores de riesgo metabólicos tradicionales. Se realizó un análisis transcriptómico de biopsias de estos pacientes, cuyo análisis reveló mecanismos alternativos para el desarrollo de IMID-MASLD, identificando genes y vías metabólicas diferencialmente expresadas como IGFBP2, DRD1 y las metalotioneínas. Se realizaron también estudios in-vitro, consiguiendo modificar el proceso de captación lipídica de hepatocitos y organoides hepáticos mediante la adición de moléculas moduladoras dopaminérgicas.},
abstract = {The prevalence of immune-mediated inflammatory diseases (IMIDs) is elevated among individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). To investigate this association, a cross-sectional case-control study was conducted. The findings demonstrated a higher prevalence of advanced forms of steatotic liver disease (SLD) and MASLD in patients with IMIDs, independent of conventional metabolic risk factors. Transcriptomic analysis of liver biopsies from these patients identified alternative pathogenic mechanisms underlying IMID-MASLD, revealing differentially expressed genes and metabolic pathways, including IGFBP2, DRD1, and metallothioneins. Additionally, in-vitro experiments were performed, modulating the lipid uptake process in hepatocytes and liver organoids through the administration of dopaminergic regulatory molecules.},
organization = {This Ph. D. Thesis has been carried out jointly at the Department of Molecular Biology of the Faculty of Medicine at the University of Cantabria and at the Marqués de Valdecilla Research Institute (IDIVAL) in Santander. The necessary funding has been provided by the Carlos III Institute through the PI18/01304 INSTInCT project (active between 2019-2022) and the PI20/01279 MINERVA project (active between 2021-2024).},
title = {Caracterización clínica y molecular de la enfermedad hepática grasa en el contexto de las enfermedades inflamatorias inmunomediadas},
author = {García Nieto, Enrique},
}